Trail Receptor 2 Agonists Pipeline Insight
DelveInsight’s, “TRAIL Receptor 2 Agonists - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL Receptor 2 Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
TRAIL Receptor 2 Agonists Understanding
TRAIL Receptor 2 Agonists: Overview
TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis
The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL Receptor 2 Agonists R&D. The therapies under development are focused on novel approaches for TRAIL Receptor 2 Agonists.
TRAIL Receptor 2 Agonists Emerging Drugs Chapters
This segment of the TRAIL Receptor 2 Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TRAIL Receptor 2 Agonists Emerging Drugs
INBRX-109 is a tetravalent DR5 agonistic antibody, is designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of our sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
BI 905711: Travere Therapeutics
BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells. BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.
Further product details are provided in the report……..
TRAIL Receptor 2 Agonists: Therapeutic Assessment
This segment of the report provides insights about the different TRAIL Receptor 2 Agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TRAIL Receptor 2 Agonists
There are approx. 5+ key companies which are developing the TRAIL Receptor 2 Agonists. The companies which have their TRAIL Receptor 2 Agonists drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
TRAIL Receptor 2 Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TRAIL Receptor 2 Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL Receptor 2 Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL Receptor 2 Agonists drugs.
TRAIL Receptor 2 Agonists Report Insights
- TRAIL Receptor 2 Agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
TRAIL Receptor 2 Agonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TRAIL Receptor 2 Agonists drugs?
- How many TRAIL Receptor 2 Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRAIL Receptor 2 Agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TRAIL Receptor 2 Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TRAIL Receptor 2 Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?